Direct measurement of in vivo BCR::ABL1 kinase inhibition reveals stronger potency of asciminib as compared with imatinib and nilotinib

Kok CH et al. Leukemia, June 2026 (epub ahead of print) – open access publication

• Share
• Tweet
• Share
• Share